SP 16
Alternative Names: Serpin Peptide 16; SP-16Latest Information Update: 03 Jun 2024
At a glance
- Originator Serpin Pharma
- Developer Serpin Pharma; Virginia Commonwealth University
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antihyperglycaemics; Cardiovascular therapies; Oligopeptides; Peptides; Serpins; Skin disorder therapies
- Mechanism of Action Immunomodulators; LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Inflammation; Myocardial infarction; SARS-CoV-2 acute respiratory disease
- Preclinical Acute kidney injury; Atopic dermatitis; Chronic inflammatory demyelinating polyradiculoneuropathy; Eosinophilic oesophagitis
- Research Alopecia areata; Neuropathic pain; Pemphigus vulgaris
- No development reported Diabetes mellitus; Myocardial reperfusion injury
Most Recent Events
- 23 May 2024 Serpin Pharma terminates a phase I/II trial in SARS-COV-2 acute respiratory disease in USA (SC), due to lack of patients (NCT05135624)
- 28 Jul 2022 SP 16 is still in phase-I/II trial for Myocardial infarction in USA (Serpin Pharma pipeline, July 2022)
- 28 Jul 2022 Early research in Alopecia areata in USA (unspecified route) (Serpin Pharma pipeline, July 2022)